Assessment of macrophage activation syndrome in Still's disease: retrospective chart analysis of patient history, symptom resolution and treatment characteristics in Italy
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Overall survival
Timeframe: from 2012 to 2022 (data abdstraction period)
Time to laboratory value normalization
Timeframe: up to 24 weeks
Time to MAS laboratory remission
Timeframe: up to 24 weeks
Time to partial MAS laboratory remission
Timeframe: up to 24 weeks
Time to tapering of GCs
Timeframe: from index date to the last of 7 consecutive days receiving ≤1 mg/kg/day of prednisone (PDN) equivalent dose
Number of recurrent MAS episodes
Timeframe: from hospital discharge or 26-weeks from the index date, whichever occurs later, until the end of study data collection]
Administration of organ support care
Timeframe: from the index date until either the hospital discharge or 26 weeks, whichever occurs later
Characteristics of MAS treatment
Timeframe: up to 24 weeks
Clinical signs
Timeframe: at index date and 8 weeks after index date (allowed time window 6 to 12 weeks)